OTTAWA, Ontario–(BUSINESS WIRE)–Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), a life
sciences corporation focused on developing and commercializing products
for livestock, companion animal and human applications that, by safely
supporting immune function, promote general health and performance,
announces the appointments of Mr. Kym Anthony to the position of C.E.O.
and Mr. Jeffrey Kraws, a director of the Corporation, to the position of
Chairman of the Board. Mr. Anthony previously held the dual role of
interim C.E.O. and Chairman. In light of Mr. Anthony’s appointment as
Avivagen’s permanent C.E.O. he has stepped down as Chairman but will
remain on the board.
Well-known and respected on Wall Street, Mr. Kraws has received some of
the most prestigious awards in the industry, including having been
consistently ranked among the Top Ten Analysts for pharmaceutical stock
performance in the world for almost two decades; as well as previously
having been ranked highest for stock performance for pharmaceuticals by
Starmine and for estimates by Zacks.
Mr. Kraws is currently CEO of Crystal Research Associates and partner at
CRA Advisors. Previously Mr. Kraws served as co-president of The
Investor Relations Group (IRG); managing director of healthcare research
for Ryan Beck & Co.; and director of research/senior pharmaceutical
analyst and managing director at Gruntal & Company. Mr. Kraws has also
served as managing director of the healthcare research group and senior
pharmaceutical analyst at First Union Securities (formerly EVEREN
Securities); as senior U.S. pharmaceutical analyst for the Swedish-Swiss
conglomerate Asea Brow Boveri; and as managing director and president of
the brokerage/investment banking operation of ABB Aros Securities, Inc.
Mr. Kraws has also served as head of competitive analysis within the
treasury group at Bristol-Myers Squibb Company.
In addition to serving as CEO of Crystal Research Associates, Mr. Kraws
is currently chairman of Synthetic Biologics Inc., a NYSE-listed
biotechnology company, a partner and co-founder of TopHat Capital, LLC.,
president of Ra Medical Systems; an NYSE medical device company, and an
Industry Advisor in healthcare investment banking for Piper Jaffray an
NYSE listed leading investment bank and investment management firm.
Through his years of experience, Mr. Kraws has cultivated a wealth of
industry knowledge and a level of credible, insightful equity analysis
that few share. As a result, he has provided guest commentary for many
network news programs, including Bloomberg, FOX Business, and CNBC,
among others, and has become a valuable resource for financial
journalists from the New York Times, Forbes, Bloomberg, CBS MarketWatch,
and MedAdNews, among other publications.
Mr. Kraws holds an MBA from Cornell University and a B.S. from State
University of New York, Buffalo.
About Avivagen
Avivagen is a life sciences corporation focused on developing and
commercializing products for livestock, companion animal and human
applications that, by safely supporting immune function, promote general
health and performance. It is a public corporation traded on the TSX
Venture Exchange under the symbol VIV and is headquartered in Ottawa,
Canada, based in partnership facilities of the National Research Council
of Canada and Charlottetown, Prince Edward Island. For more information,
visit www.avivagen.com.
The contents of the website are expressly not incorporated by reference
in this press release.
About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries
about carotenoids, compounds that give certain fruits and vegetables
their bright colours, and is a non-antibiotic means of maintaining
optimal health and growth. OxC-beta™ Livestock is a proprietary product
shown to be effective and economic in replacing the antibiotics commonly
added to livestock feeds. OxC-beta™ Livestock is currently registered
and available for sale in the United States, Philippines, Taiwan, New
Zealand and Thailand.
Avivagen’s OxC-beta™ Livestock product is safe, effective and could
fulfill the global mandate to remove all in-feed antibiotics as growth
promoters. Numerous international livestock trials with poultry and
swine using OxC-beta™ Livestock have proven that the product performs as
well as, and, sometimes, in some aspects, better than in-feed
antibiotics.
About Vivamune™ Health Chews (Vivamune™)
Vivamune™ is an all-in-one chew that can dramatically simplify a
pet’s supplement routine. Featuring a newly-discovered, novel
immune-supporting active ingredient, OxC-beta™, Vivamune™ targets
joints, skin and digestive health all in a single, tasty chew a pet will
love. Vivamune™ is available for sale in the United States,
Canada, Philippines, Taiwan and New Zealand. For more information, visit www.vivamunehealth.com.
The contents of the website are expressly not incorporated by reference
in this press release.
Forward Looking Statements
This news release includes certain forward-looking statements that
are based upon the current expectations of management. Forward-looking
statements involve risks and uncertainties associated with the business
of Avivagen Inc. and the environment in which the business operates. Any
statements contained herein that are not statements of historical facts
may be deemed to be forward-looking, including those identified by the
expressions “aim”, “anticipate”, “appear”, “believe”, “consider”,
“could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”,
“may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”,
“whether”, “will”, “would” and similar expressions. Statements regarding
the potential for OxC-beta™ Livestock to fulfill the global mandate to
remove all in-feed antibiotics as growth promoters are forward looking
statements. Forward-looking statements are subject to a number of
risks and uncertainties that could cause actual results or events to
differ materially from current expectations. For instance, Avivagen’s
products may not gain market acceptance or regulatory approval in new
jurisdictions or for new applications and may not be widely accepted as
a replacement for antibiotics in livestock feeds due to many factors,
many of which are outside of Avivagen’s control. Except as
required by law, Avivagen assumes no obligation to update the
forward-looking statements, or to update the reasons why actual results
could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Copyright © 2019 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.
Contacts
Avivagen Inc.
Drew Basek
Director of Investor Relations
100
Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Phone: 416-540-0733
E-mail:
d.basek@avivagen.com
Kym Anthony
Chief Executive Officer
100 Sussex Drive, Ottawa,
Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164
Website:
www.avivagen.com